Alnylam Pharmaceuticals
ALNY
$205.52
+0.02%
Alnylam Pharmaceuticals is a biotechnology leader pioneering RNA interference (RNAi) therapeutics, with approved products including Onpattro, Amvuttra, Givlaari, and Oxlumo, and partnered drugs Leqvio and Qfitlia. As the dominant player in the RNAi space, it has established a robust platform and commercial infrastructure that differentiates it from peers. The current investor narrative centers on the company's transition to profitability, driven by accelerating revenue growth from its core products and pipeline expansion into large markets like cardio-metabolic and neuroscience, though valuation concerns and competitive risks remain debated.…
ALNY
Alnylam Pharmaceuticals
$205.52
Related headlines
Investment Opinion: Should I buy ALNY Today?
Rating: Buy. Alnylam is a compelling investment given its fundamental inflection to profitability, accelerating revenue growth, and substantial analyst upside. The consensus analyst rating is Buy with an average target of $432.04, implying 59% upside from $271.77.
Supporting Evidence: Q1 2026 revenue grew 96.4% YoY to $1.167B, net income turned positive at $206M, operating margin improved to 23.0% from 3.0%, and free cash flow turned positive. The forward P/E of 20.2x is in line with industry averages, while the trailing P/E of 166.4x reflects past losses. The PS ratio of 14.0x is elevated but justified by the growth rate. The company has a healthy current ratio of 2.76 and $1.712B in cash.
Risks & Conditions: Key risks include failure to sustain growth, gross margin compression, and pipeline setbacks. This Buy would downgrade to Hold if revenue growth decelerates below 50% YoY or if the stock fails to hold above $262 support. Upgrade to Strong Buy if the stock breaks above $320 resistance with volume. Overall, ALNY appears undervalued relative to its growth trajectory and analyst targets, but fairly valued on a forward P/E basis.
Sign up to view all
ALNY 12-Month Price Forecast
Alnylam's fundamental inflection is compelling, with revenue growth accelerating to 96.4% and profitability achieved. The forward P/E of 20.2x is attractive relative to the growth rate, and analyst targets suggest significant upside. However, the stock's technical downtrend and high trailing P/E warrant caution. The base case of 50% probability assumes continued growth and margin expansion, driving the stock toward the average target of $432. A bullish stance is justified by the strong fundamentals, but confidence is medium due to execution risk and market skepticism. Upgrades would come from sustained revenue growth above 50% and positive pipeline catalysts; downgrades from margin deterioration or clinical failures.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Alnylam Pharmaceuticals's 12-month outlook, with a consensus price target around $427.61 and implied upside of +108.1% versus the current price.
Average Target
$427.61
0 analysts
Implied Upside
+108.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$310 - $536
Analyst target range
Alnylam is covered by 23 analysts, with a consensus recommendation of 'Buy' (mean rating 1.78 on a 1-5 scale, where 1 is Strong Buy). The average target price is $432.04, implying a substantial 59.0% upside from the current price of $271.77. The distribution leans heavily bullish, with recent ratings from B of A Securities, Truist Securities, and HC Wainwright all reiterating Buy ratings in July 2026. The target range spans from a low of $285.00 to a high of $551.00. The high target of $551 assumes successful pipeline expansion and sustained revenue growth, potentially driving multiple expansion. The low target of $285 suggests only modest upside and may reflect risks such as competitive pressure or slower-than-expected adoption. The wide spread between low and high ($266) indicates significant uncertainty about the company's future performance. Recent analyst actions show no downgrades, with firms maintaining positive stances, which reinforces the bullish consensus. However, the stock's current price well below the low target suggests the market is pricing in more risk than analysts, possibly due to near-term headwinds or skepticism about growth sustainability.
Drowning in data?
Find the real signal!
Bulls vs Bears: ALNY Investment Factors
Alnylam presents a compelling turnaround story with accelerating revenue growth, achieved profitability, and a strong balance sheet. The bull case is supported by a 96.4% YoY revenue surge, positive net income of $206M, and a consensus analyst target implying 59% upside. However, the stock trades at a lofty trailing P/E of 166.4x and is in a sustained downtrend, having lost 17.1% over the past year. The key tension is whether the company can sustain its growth trajectory to justify its valuation—if earnings materialize as expected, the forward P/E of 20.2x is reasonable, but any disappointment could lead to further downside. Currently, the bull case has stronger evidence given the fundamental inflection, but the stock's technical weakness warrants caution.
Bullish
- Revenue Growth Accelerating: Q1 2026 revenue surged 96.4% YoY to $1.167 billion, driven by strong product sales. The multi-quarter trend shows consistent acceleration from $594M in Q1 2025 to $1.167B in Q1 2026, indicating robust commercial execution.
- Achieved Profitability Milestone: Net income turned positive at $206 million in Q1 2026, compared to a net loss of $57.5 million in Q1 2025. Operating margin improved dramatically to 23.0% from 3.0% a year ago, demonstrating significant operating leverage.
- Strong Analyst Consensus: 23 analysts rate ALNY a Buy with a mean rating of 1.78 (1=Strong Buy). The average target price of $432.04 implies 59.0% upside from the current price of $271.77, with a high target of $551 suggesting substantial potential.
- Healthy Balance Sheet: Current ratio of 2.76 and cash of $1.712 billion provide ample liquidity. Free cash flow turned positive at $48.7 million in Q1 2026, versus negative $127.3 million a year ago, reducing financial risk.
Bearish
- High Trailing P/E Multiple: Trailing P/E of 166.4x is far above the biotechnology industry average of 20-30x, reflecting extreme optimism. Even with expected earnings growth, the stock trades at a premium that leaves little room for error.
- Stock in Sustained Downtrend: ALNY has declined 17.1% over the past year and is trading near its 52-week low of $262.21. The stock has underperformed the S&P 500 by 33.6% over one year, indicating persistent selling pressure.
- Valuation Depends on Growth: Forward P/E of 20.2x implies dramatic earnings growth, but any miss could trigger multiple compression. The PEG ratio is negative (-0.79), suggesting the market expects earnings growth to decelerate.
- Competitive and Pipeline Risks: As a biotech, ALNY faces competition from other modalities and pipeline setbacks. The wide analyst target range ($285-$551) reflects high uncertainty about future product approvals and market adoption.
ALNY Technical Analysis
ALNY is in a sustained downtrend, with the stock declining 17.1% over the past year and currently trading at 54.8% of its 52-week range (price $271.77 vs. 52-week low of $262.21 and high of $495.55). This positioning near the low end suggests bearish sentiment and potential value opportunity, but also risk of further downside if fundamentals deteriorate. The stock has underperformed the S&P 500 significantly, with a relative strength of -33.6% over one year. Short-term momentum is decisively negative, with a 1-month price change of -7.6% and a 3-month change of -11.1%, both contrasting sharply with the S&P 500's gains of +0.8% and +3.5% over the same periods. This divergence indicates persistent selling pressure and a lack of buying interest, with the stock failing to participate in the broader market rally. The RSI is not provided, but the consistent decline suggests oversold conditions may be developing, though no reversal signal is evident yet. Key support lies at the 52-week low of $262.21, a break below which could accelerate selling toward the $250 area. Resistance is at the 52-week high of $495.55, a level that seems distant given current momentum. The stock's beta of 0.27 indicates it is significantly less volatile than the market, meaning the downtrend is more company-specific than macro-driven, and any recovery may be gradual.
Beta
—
—
Max Drawdown
-58.2%
Largest decline past year
52-Week Range
$198-$496
Price range past year
Annual Return
-47.6%
Cumulative gain past year
| Period | ALNY Return | S&P 500 |
|---|---|---|
| 1m | -31.9% | +0.2% |
| 3m | -30.6% | +3.7% |
| 6m | -39.2% | +8.0% |
| 1y | -47.6% | +18.2% |
| ytd | -48.6% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALNY Fundamental Analysis
Alnylam's revenue trajectory has been robust, with Q1 2026 revenue of $1.167 billion, representing a 96.4% year-over-year growth rate. This growth is driven by strong product sales, particularly Givlaari ($74.4 million in the quarter) and the overall product revenue of $1.036 billion. The multi-quarter trend shows accelerating growth: revenue was $594 million in Q1 2025, $774 million in Q2 2025, $1.249 billion in Q3 2025, and $1.097 billion in Q4 2025, indicating a sustained ramp-up. The company has achieved profitability, with net income of $206 million in Q1 2026 compared to a net loss of $57.5 million in the same quarter last year. Gross margin remains strong at 81.9%, though slightly down from 88.0% in Q1 2025, likely due to product mix. Operating margin improved dramatically to 23.0% from 3.0% a year ago, reflecting operating leverage as revenue scales. The company's balance sheet is healthy, with a current ratio of 2.76 and cash at end of period of $1.712 billion. Free cash flow was $48.7 million in Q1 2026, positive for the second consecutive quarter, compared to negative free cash flow of $127.3 million in Q1 2025. Debt-to-equity stands at 1.62, but given the strong cash position and positive cash flow, financial risk appears manageable. ROE is 39.8%, indicating efficient use of equity capital.
Quarterly Revenue
$1.2B
2026-03
Revenue YoY Growth
+96.4%
YoY Comparison
Gross Margin
81.9%
Latest Quarter
Free Cash Flow
$641338000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALNY Overvalued?
Since net income is positive (TTM net income of $577 million), the trailing P/E ratio of 166.4x is the primary valuation metric. The forward P/E of 20.2x implies a dramatic compression, reflecting market expectations of significant earnings growth. The gap between trailing and forward P/E suggests the market anticipates a sharp increase in profitability, which is supported by the recent earnings trajectory. Compared to the biotechnology industry, Alnylam's trailing P/E of 166.4x is far above the industry average (typically around 20-30x for profitable biotechs), representing a substantial premium. However, the forward P/E of 20.2x is more in line with industry norms, indicating that the current price already prices in expected earnings growth. The PS ratio of 14.0x is also elevated relative to the industry average of around 5-8x, reflecting the high growth premium. Historically, Alnylam's trailing P/E has ranged from negative (during loss years) to over 200x. The current trailing P/E of 166.4x is near the higher end of its historical range, suggesting the market is pricing in optimistic future earnings. The forward P/E of 20.2x is near the lower end of historical forward multiples, implying that if earnings materialize as expected, the stock could be reasonably valued.
PE
166.4x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 38x~71x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
81.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Alnylam's high trailing P/E of 166.4x leaves it vulnerable to earnings misses. While the company turned profitable in Q1 2026, its net margin is still only 8.4%, and gross margin declined from 88.0% to 81.9% YoY. The debt-to-equity ratio of 1.62 is elevated, though manageable given $1.712 billion in cash. Revenue concentration in a few products (Onpattro, Amvuttra, Givlaari, Oxlumo) poses risk if any faces competition or regulatory setbacks. Free cash flow turned positive but was only $48.7 million in Q1 2026, limiting financial flexibility.
Market & Competitive Risks: The stock's beta of 0.27 indicates low market correlation, but its 17.1% annual decline shows company-specific weakness. Valuation compression risk is high if growth decelerates—the forward P/E of 20.2x assumes significant earnings expansion. Competitive threats from other RNAi players or alternative modalities could erode market share. Regulatory headwinds, such as pricing pressure or FDA scrutiny, could impact product launches. The recent news highlights analyst optimism, but the stock's price well below the low analyst target ($285) suggests the market is pricing in more risk than analysts.
Worst-Case Scenario: A combination of pipeline setbacks, slower-than-expected revenue growth, and margin compression could drive the stock to its 52-week low of $262.21 or below. If earnings fail to meet forward expectations, the P/E could contract further, potentially pushing the stock to $250 (a 8% decline from current levels). In a severe scenario, a major clinical failure or competitive displacement could lead to a -35% decline to the 52-week low of $262.21, representing a loss of $9.56 per share from the current price of $271.77.
FAQ
The primary risk is execution: if revenue growth decelerates below 50% or margins compress, the stock could fall to the analyst low target of $285 or below. Financial risk is moderate with a debt-to-equity of 1.62, but the cash position of $1.712 billion provides a buffer. Competitive risk from other RNAi therapies or alternative modalities could erode market share. Macro risk is low given the beta of 0.27, but a broad biotech sell-off could still pressure the stock. The most severe risk is a clinical trial failure in a key pipeline program, which could trigger a -35% decline to the 52-week low of $262.21.
The 12-month forecast is bullish with a base case probability of 50% targeting $320-$432, driven by continued revenue growth and margin expansion. The bull case (30% probability) sees the stock reaching $432-$551 on strong pipeline catalysts, while the bear case (20% probability) could see a decline to $250-$285 if growth disappoints. The most likely scenario is the base case, assuming the company sustains 30-40% revenue growth and improves operating margins. Analyst consensus supports this view with an average target of $432.04.
ALNY's trailing P/E of 166.4x is significantly overvalued compared to the biotech industry average of 20-30x, reflecting the market's high expectations for future earnings. However, the forward P/E of 20.2x is in line with industry norms, suggesting that if earnings materialize as expected, the stock is fairly valued. The PS ratio of 14.0x is above the industry average of 5-8x, indicating a premium for growth. Historically, the trailing P/E has ranged from negative to over 200x, so the current level is near the high end. Overall, the stock is priced for perfection, but the growth trajectory justifies the premium if sustained.
ALNY appears to be a good buy for growth-oriented investors willing to tolerate near-term volatility. The company has achieved a fundamental inflection with 96.4% revenue growth and positive net income of $206 million in Q1 2026. Analyst consensus is Buy with an average target of $432.04, implying 59% upside from the current price of $271.77. However, the stock is in a downtrend and trades near its 52-week low, so investors should be prepared for potential further declines. The biggest risk is that growth decelerates, which could compress the forward P/E of 20.2x. For those with a 12-month horizon, the risk/reward is favorable given the strong fundamentals and analyst support.
ALNY is better suited for long-term investment given its growth stage and volatility. The stock has a beta of 0.27, indicating low market correlation, but its 17.1% annual decline shows company-specific risk. Short-term trading is risky due to the downtrend and proximity to the 52-week low. For long-term investors, the RNAi platform provides a multi-year growth runway, and the company's path to profitability reduces dilution risk. A minimum holding period of 3-5 years is recommended to allow pipeline catalysts to materialize and earnings to compound. The stock pays no dividend, so total return depends on capital appreciation.
